Oligometastatic bone disease in prostate cancer patients treated on the TROG 03.04 RADAR trial.
CONCLUSION: Randomised trials are essential to determine the value of extirpative treatment for oligometastatic bony metastases due to PC. PMID: 27528117 [PubMed - as supplied by publisher]
Patients with non-Hodgkin's lymphoma who received radiation 30 days or less...Read more on AuntMinnie.comRelated Reading: ASTRO: AI predicts side effects from radiation therapy ASTRO: Is hormone therapy after prostate surgery needed? ASTRO: SABR generates immune response to prostate cancer ASTRO: Cervical cancer deaths rise as women's centers close ASTRO: Whole, partial breast RT yield similar cosmetic results
Just one high dose of radiation to the heart can significantly reduce episodes...Read more on AuntMinnie.comRelated Reading: ASTRO: AI predicts side effects from radiation therapy ASTRO: Is hormone therapy after prostate surgery needed? ASTRO: SABR generates immune response to prostate cancer ASTRO: Cervical cancer deaths rise as women's centers close ASTRO: Whole, partial breast RT yield similar cosmetic results
Localized prostate cancer (PCa) has a high cure rate of 95.5%. PCa patients receive radiation therapy (RT) as a standard of care treatment. However, the major concern is the treatment-related side effects compromising the quality of life (QoL) in PCa patients. Radiation-induced Erectile Dysfunction (RiED) is a common and irreversible late side effect of RT, that develops in more than half of PCa patients. There is no FDA approved drug to treat RiED. Phosphodiesterase type 5 inhibitors (PDE5i) are the most common pharmacological agents being used to treat RiED.
Salvage radiation therapy (SRT) is recommended for men with biochemically recurrent prostate cancer post-radical prostatectomy. RTOG 9601 was a randomized phase 3 clinical trial that demonstrated an overall survival (OS) benefit from the addition of long-term anti-androgen therapy to SRT. However, hormone therapy has well documented side effects and has been shown to increase cardiac event rates, and there remains no evidence of an OS benefit from hormone therapy for men treated with early SRT. Herein, we aim to determine if pre-SRT PSA can serve as both a prognostic and predictive biomarker of benefit or harm from hormone therapy.
Healthcare systems are often compared with the aviation industry. Progress in both is highly desired but must always be achieved with safety in mind. Everyone wants to get from point A to point B faster and more comfortably, but how much risk of uncertainty is one ready to accept to achieve that extra speed? Both industries also share the aspect of competition for customers. In the field of localized prostate cancer, patients have an ever-increasing choice of options: radical surgery (open vs laparoscopic vs robot-assisted), external beam radiation therapy (EBRT) (with photons or protons), brachytherapy (low-dose rate or h...
High-dose, precision radiation therapy extends progression-free survival in recurrent prostate cancer with limited metastatic spread and prevents the development of new lesions at 6 months.Medscape Medical News
Authors: Morgentaler A, Caliber M Abstract Introduction: The use of testosterone therapy (TTh) in men with prostate cancer (PCa) is relatively new, and controversial, due to the longstanding maxim that TTh is contraindicated in men with PCa. Scientific advances have prompted a reevaluation of the potential role for TTh in men with PCa, particularly as TTh has been shown to provide important symptomatic and general health benefits to men with testosterone deficiency (TD), including many men with PCa who may expect to live 30-50 years after diagnosis. Areas covered: This review outlines the historical underpinnings o...
This report demonstrates a patient with high PSA levels (856 ng/mL) at time of biochemical recurrence that showed only 1 metastasis on PSMA PET/CT. Combined androgen deprivation therapy and radiation therapy resulted in a complete biochemical response.
Abstract PURPOSE: Systemic androgen-signaling inhibition added to ongoing androgen-deprivation therapy (ADT) improved clinical outcomes in patients with nonmetastatic castration-resistant prostate cancer without detectable metastases by conventional imaging (nmCRPC). Prostate-specific membrane antigen ligand positron-emission tomography (PSMA-PET) detects prostate cancer with superior sensitivity to conventional imaging, but its performance in nmCRPC remains largely unknown. We characterized cancer burden in high-risk nmCRPC patients using PSMA-PET. EXPERIMENTAL DESIGN: We retrospectively included 200 patient...
CONCLUSION: There is increasing variation among group practices in the use of conservative management for prostate cancer. This underscores the need for a better understanding of practice-level factors that influence prostate cancer management. PMID: 31509481 [PubMed - as supplied by publisher]